Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for
neuroblastoma and medulloblastoma. An investigational drug is one that has not yet been
approved by the Food and Drug Administration. This investigational drug is called TPI 287.
This study will look at the tumor's response to the study drug, TPI 287, as well as the
safety and tolerability of the drug.
TPI 287 was shown to be effective in stopping tumor growth and was also shown to be safe in
three different animal species. TPI 287 has been tested in humans in four clinical trials,
and approximately 100 subjects with various types of cancers have received the drug,
including a pediatric population in our previous Phase I trial.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Giselle SaulnierSholler Giselle Sholler
Collaborators:
Cortice Biosciences, Inc. Van Andel Research Institute